FDA to Consider Easing Restrictions on Unproven Peptides

The meeting follows calls from Health Secretary Robert F. Kennedy Jr. to loosen regulations on the unapproved therapies.

Apr. 15, 2026 at 1:55pm

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray image revealing the internal structures of a human joint or muscle, glowing against a dark background to conceptually represent the biological effects of peptide therapies.An X-ray view into the complex biological mechanisms targeted by controversial peptide therapies, which the FDA is now reconsidering for wider access.Washington Today

The Food and Drug Administration will hold a meeting this summer to consider easing restrictions on more than a half dozen peptide injections, a group of unapproved therapies that have become popular among wellness influencers, fitness gurus and celebrities. The move follows repeated pledges by Health Secretary Robert F. Kennedy Jr. to loosen regulations on peptides, which are often pitched as a quick way to build muscle, heal injuries or appear younger.

Why it matters

The FDA's decision could have significant implications for the growing market of unregulated peptide products, which are often sold online or through wellness clinics with little oversight. Critics argue these substances present safety risks, while proponents claim they offer health benefits despite limited research.

The details

The FDA said it will ask a panel of outside pharmacy advisers to review seven peptides at a meeting in July, specifically whether they should be moved from a restrictive category reserved for risky, customized drugs. The drugs include some of the most popular peptides among influencers, such as BPC-157, which is marketed to heal injuries and reduce inflammation. Under the Biden administration, the FDA had previously added more than a dozen of the most popular peptides to the federal list of substances that should not be produced by compounding pharmacies.

  • The FDA meeting is scheduled for July 2026.
  • In 2023, the FDA added a number of injectable peptides to its list of restricted substances, citing safety risks.

The players

Robert F. Kennedy Jr.

The current U.S. Health Secretary who has repeatedly called for loosening regulations on peptides, which he has discussed using for his own injuries.

Gary Brecka

A self-described 'longevity expert' who sells various peptide formulas through his website and is a major supporter of Kennedy's Make America Healthy Again movement.

Food and Drug Administration (FDA)

The federal agency that regulates the safety and efficacy of drugs and medical products in the United States.

Got photos? Submit your photos here. ›

What they’re saying

“I'm a big fan of peptides. I've used them myself and with really good effect on a couple of injuries.”

— Robert F. Kennedy Jr., Health Secretary

“With the gray market you have no idea if you're getting a good product. And a lot of this stuff that we've looked at is just very, very substandard.”

— Robert F. Kennedy Jr., Health Secretary

What’s next

The FDA panel of outside pharmacy advisers will meet in July 2026 to review the seven peptides and consider whether they should be moved to a less restrictive category that would allow for routine compounding by pharmacies.

The takeaway

The FDA's decision on peptides could have far-reaching implications for the growing market of unregulated wellness products, with proponents arguing for greater access and critics concerned about safety risks. This debate highlights the ongoing tensions between consumer demand for alternative therapies and the need for rigorous scientific review.